Literature DB >> 20353362

Challenge pools of hepatitis C virus genotypes 1-6 prototype strains: replication fitness and pathogenicity in chimpanzees and human liver-chimeric mouse models.

Jens Bukh1, Philip Meuleman, Raymond Tellier, Ronald E Engle, Stephen M Feinstone, Gerald Eder, William C Satterfield, Sugantha Govindarajan, Krzysztof Krawczynski, Roger H Miller, Geert Leroux-Roels, Robert H Purcell.   

Abstract

Chimpanzees represent the only animal model for studies of the natural history of hepatitis C virus (HCV). To generate virus stocks of important HCV variants, we infected chimpanzees with HCV strains of genotypes 1-6 and determined the infectivity titer of acute-phase plasma pools in additional animals. The courses of first- and second-passage infections were similar, with early appearance of viremia, HCV RNA titers of >10(4.7) IU/mL, and development of acute hepatitis; the chronicity rate was 56%. The challenge pools had titers of 10(3)-10(5) chimpanzee infectious doses/mL. Human liver-chimeric mice developed high-titer infections after inoculation with the challenge viruses of genotypes 1-6. Inoculation studies with different doses of the genotype 1b pool suggested that a relatively high virus dose is required to consistently infect chimeric mice. The challenge pools represent a unique resource for studies of HCV molecular virology and for studies of pathogenesis, protective immunity, and vaccine efficacy in vivo.

Entities:  

Mesh:

Year:  2010        PMID: 20353362      PMCID: PMC2941994          DOI: 10.1086/651579

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  48 in total

1.  Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA.

Authors:  A A Kolykhalov; E V Agapov; K J Blight; K Mihalik; S M Feinstone; C M Rice
Journal:  Science       Date:  1997-07-25       Impact factor: 47.728

2.  Nucleotide sequence of the genomic RNA of hepatitis C virus isolated from a human carrier: comparison with reported isolates for conserved and divergent regions.

Authors:  H Okamoto; S Okada; Y Sugiyama; K Kurai; H Iizuka; A Machida; Y Miyakawa; M Mayumi
Journal:  J Gen Virol       Date:  1991-11       Impact factor: 3.891

3.  Hepatitis C virus subtyping by a core-envelope 1-based reverse transcriptase PCR assay with sequencing and its use in determining subtype distribution among Danish patients.

Authors:  Sylvie Corbet; Jens Bukh; Anja Heinsen; Anders Fomsgaard
Journal:  J Clin Microbiol       Date:  2003-03       Impact factor: 5.948

4.  In vivo study of the HC-TN strain of hepatitis C virus recovered from a patient with fulminant hepatitis: RNA transcripts of a molecular clone (pHC-TN) are infectious in chimpanzees but not in Huh7.5 cells.

Authors:  Akito Sakai; Shingo Takikawa; Robert Thimme; Jean-Christophe Meunier; Hans Christian Spangenberg; Sugantha Govindarajan; Patrizia Farci; Suzanne U Emerson; Francis V Chisari; Robert H Purcell; Jens Bukh
Journal:  J Virol       Date:  2007-04-04       Impact factor: 5.103

5.  Current status of a hepatitis C vaccine: encouraging results but significant challenges ahead.

Authors:  Marianne Mikkelsen; Jens Bukh
Journal:  Curr Infect Dis Rep       Date:  2007-03       Impact factor: 3.725

6.  Hepatitis C virus: an infectious molecular clone of a second major genotype (2a) and lack of viability of intertypic 1a and 2a chimeras.

Authors:  M Yanagi; R H Purcell; S U Emerson; J Bukh
Journal:  Virology       Date:  1999-09-15       Impact factor: 3.616

7.  Polyclonal immunoglobulins from a chronic hepatitis C virus patient protect human liver-chimeric mice from infection with a homologous hepatitis C virus strain.

Authors:  Thomas Vanwolleghem; Jens Bukh; Philip Meuleman; Isabelle Desombere; Jean-Christophe Meunier; Harvey Alter; Robert H Purcell; Geert Leroux-Roels
Journal:  Hepatology       Date:  2008-06       Impact factor: 17.425

8.  Long-term persistence of infection in chimpanzees inoculated with an infectious hepatitis C virus clone is associated with a decrease in the viral amino acid substitution rate and low levels of heterogeneity.

Authors:  Javier Fernandez; Deborah Taylor; Duncan R Morhardt; Kathleen Mihalik; Montserrat Puig; Charles M Rice; Stephen M Feinstone; Marian E Major
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

9.  Experimental infection of chimpanzees with hepatitis C virus of genotype 5a: genetic analysis of the virus and generation of a standardized challenge pool.

Authors:  J Bukh; C L Apgar; R Engle; S Govindarajan; P A Hegerich; R Tellier; D C Wong; R Elkins; M C Kew
Journal:  J Infect Dis       Date:  1998-10       Impact factor: 5.226

10.  Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization.

Authors:  Troels K H Scheel; Judith M Gottwein; Tanja B Jensen; Jannick C Prentoe; Anne M Hoegh; Harvey J Alter; Jesper Eugen-Olsen; Jens Bukh
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-14       Impact factor: 11.205

View more
  38 in total

1.  A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo.

Authors:  Philip Meuleman; Maria Teresa Catanese; Lieven Verhoye; Isabelle Desombere; Ali Farhoudi; Christopher T Jones; Timothy Sheahan; Katarzyna Grzyb; Riccardo Cortese; Charles M Rice; Geert Leroux-Roels; Alfredo Nicosia
Journal:  Hepatology       Date:  2011-12-16       Impact factor: 17.425

2.  Hepatitis C homolog in dogs with respiratory illness.

Authors:  Jens Bukh
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-18       Impact factor: 11.205

3.  Broadening CD4+ and CD8+ T Cell Responses against Hepatitis C Virus by Vaccination with NS3 Overlapping Peptide Panels in Cross-Priming Liposomes.

Authors:  Jonathan Filskov; Marianne Mikkelsen; Paul R Hansen; Jan P Christensen; Allan R Thomsen; Peter Andersen; Jens Bukh; Else Marie Agger
Journal:  J Virol       Date:  2017-06-26       Impact factor: 5.103

4.  Production and characterization of high-titer serum-free cell culture grown hepatitis C virus particles of genotype 1-6.

Authors:  Christian K Mathiesen; Tanja B Jensen; Jannick Prentoe; Henrik Krarup; Alfredo Nicosia; Mansun Law; Jens Bukh; Judith M Gottwein
Journal:  Virology       Date:  2014-05-24       Impact factor: 3.616

5.  Novel infectious cDNA clones of hepatitis C virus genotype 3a (strain S52) and 4a (strain ED43): genetic analyses and in vivo pathogenesis studies.

Authors:  Judith M Gottwein; Troels K H Scheel; Benoit Callendret; Yi-Ping Li; Heather B Eccleston; Ronald E Engle; Sugantha Govindarajan; William Satterfield; Robert H Purcell; Christopher M Walker; Jens Bukh
Journal:  J Virol       Date:  2010-03-03       Impact factor: 5.103

6.  In vivo evaluation of the cross-genotype neutralizing activity of polyclonal antibodies against hepatitis C virus.

Authors:  Philip Meuleman; Jens Bukh; Lieven Verhoye; Ali Farhoudi; Thomas Vanwolleghem; Richard Y Wang; Isabelle Desombere; Harvey Alter; Robert H Purcell; Geert Leroux-Roels
Journal:  Hepatology       Date:  2011-02-11       Impact factor: 17.425

7.  Persistent human hepatitis B virus infection in cynomolgus monkeys: a novel animal model in the search for a cure?

Authors:  Jens Bukh; Robert E Lanford; Robert H Purcell
Journal:  Hepatology       Date:  2013-09-19       Impact factor: 17.425

Review 8.  Animal models for the study of HCV.

Authors:  Koen Vercauteren; Ype P de Jong; Philip Meuleman
Journal:  Curr Opin Virol       Date:  2015-05-23       Impact factor: 7.090

Review 9.  Hepatitis C Virus Postexposure Prophylaxis in the Healthcare Worker: Why Direct-Acting Antivirals Don't Change a Thing.

Authors:  Susanna Naggie; David P Holland; Mark S Sulkowski; David L Thomas
Journal:  Clin Infect Dis       Date:  2016-09-28       Impact factor: 9.079

10.  Hepatitis C Virus Genotype 1 to 6 Protease Inhibitor Escape Variants: In Vitro Selection, Fitness, and Resistance Patterns in the Context of the Infectious Viral Life Cycle.

Authors:  Stéphanie B N Serre; Sanne B Jensen; Lubna Ghanem; Daryl G Humes; Santseharay Ramirez; Yi-Ping Li; Henrik Krarup; Jens Bukh; Judith M Gottwein
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.